Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | UBE2N | P61088 | 1/20 | 0.63 |
| ▸ | CA2 | P00918 | 6/20 | 0.62 |
| ▸ | CA9 | Q16790 | 6/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.49 |
| ▸ | HTR6 | P50406 | 6/20 | 0.47 |
| ▸ | KLK7 | P49862 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6166787 | 1.00 | KDM4E (0.63) | KDM4EUBE2NCA2CA9L3MBTL1 | |
| SCHEMBL2606558 | 0.78 | KDM4E (0.58) | KDM4EUBE2NCA2CA9L3MBTL1 | |
| SCHEMBL946372 | 0.78 | KDM4E (1.00) | KDM4EUBE2NCA2CA9L3MBTL1 | |
| SCHEMBL29694480 | 0.78 | KDM4E (1.00) | KDM4EUBE2NCA2CA9L3MBTL1 | |
| SCHEMBL28207045 | 0.77 | KDM4E (0.64) | KDM4EUBE2NCA2CA9HTR6 | |
| SCHEMBL16291995 | 0.76 | KDM4E (0.80) | KDM4EUBE2NCA2CA9L3MBTL1 | |
| SCHEMBL31262899 | 0.76 | KDM4E (0.80) | KDM4EUBE2NCA2CA9L3MBTL1 | |
| SCHEMBL7828914 | 0.76 | CA2 (0.71) | KDM4EUBE2NCA2CA9L3MBTL1 | |
| SCHEMBL11909017 | 0.76 | CA2 (0.71) | KDM4EUBE2NCA2CA9L3MBTL1 | |
| SCHEMBL7828911 | 0.76 | CA2 (0.71) | KDM4EUBE2NCA2CA9L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050124620-A1 | Indole derivatives having an acidic moiety that inhibit or modulate activity of p38 map kinase mediating a disease state; e.g., 3-(2-(4-pyridyl)ethyl)-5-(3-trifluoromethoxybenzamido)indole; enzyme inhibitors; antiarthritic, -inflammatory, and -carcinogenic agents; respiratory disorders; AIDS; Alzheimer's | FREDERICKSON MARTYN (GB) | 2005-06-09 | — | — | US | disclosed |
| EP-1495016-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS MODULATORS OF P38 MAP KINASE | Astex Technology Limited (GB) | 2005-01-12 | — | — | EP | disclosed |
| WO-2003087087-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS MODULATORS OF P38 MAP KINASE | ASTEX TECHNOLOGY LIMITED (GB) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124620-A1 | Indole derivatives having an acidic moiety that inhibit or modulate activity of p38 map kinase mediating a disease state; e.g., 3-(2-(4-pyridyl)ethyl)-5-(3-trifluoromethoxybenzamido)indole; enzyme inhibitors; antiarthritic, -inflammatory, and -carcinogenic agents; respiratory disorders; AIDS; Alzheimer's | MAPK1, IDO1, INMT | KDM4E 2486/4885UBE2N 1297/4885CA2 2202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.